ArticleCureus2026
Early-Remitting Neonatal Diabetes in a Growth-Restricted Preterm Infant Requiring Insulin: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neonatal diabetes mellitus is a rare cause of persistent hyperglycemia in early infancy and is usually monogenic. We describe a male preterm neonate born at 34 weeks' gestation with intrauterine growth restriction who developed severe hyperglycemia from the first days of life. Plasma glucose reached a maximum of 570 mg/dL with persistent glycosuria, negative urine ketones, and a normal acid-base profile. C-peptide was profoundly suppressed (0.01 ng/mL), supporting marked endogenous insulin deficiency. Following optimization of glucose administration, intravenous short-acting regular human insulin was initiated with hourly glucose monitoring and complicated by early asymptomatic hypoglycemia requiring rapid correction and insulin dose reduction. As enteral feeds started, treatment was switched to micro-dosed subcutaneous short-acting regular human insulin with the use of a freshly prepared dilution and a pre-feed threshold strategy. Insulin requirements progressively decreased, and therapy was discontinued by three months of age with maintenance of normoglycemia and normal glycated hemoglobin (HbA1c). Growth and neurodevelopment were normal through two years of follow-up. This case highlights the importance of keeping neonatal diabetes in mind for preterm, growth-restricted infants with persistent severe hyperglycemia requiring insulin after exclusion of secondary causes, and also to master the details of practical safety considerations for insulin use in early life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.